<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683267</url>
  </required_header>
  <id_info>
    <org_study_id>114-03P</org_study_id>
    <nct_id>NCT00683267</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Intraoperative Localized Instillation of 4975 in Patients Undergoing Primary Unilateral Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anesiva, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anesiva, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy, safety and tolerability of a single intraoperative dose of 4975 in
      patients undergoing total hip replacement
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of a single
      intraoperative dose of 4975 in patients undergoing primary unilateral total hip arthroplasty
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment of patients has halted prematurely and will not resume. No future patients will be
    enrolled or treated.
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS) measures of pain at prespecified times</measure>
    <time_frame>Primary endpoint is 2 days (4-48 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other efficacy endpoints, safety and tolerability of 4975</measure>
    <time_frame>42 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Arthroplasty</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study treatment, 4975, is instilled directly into surgical site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is instilled directly into surgical site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4975, highly purified capsaicin</intervention_name>
    <description>One dose administered by direct instillation into the surgical site</description>
    <arm_group_label>1</arm_group_label>
    <other_name>4975, Adlea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One dose administered by direct instillation into the surgical site</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female aged 18 to 85 years with an American Society of Anesthesiologists (ASA)
             status of I, II, III

          -  Planning to undergo unilateral THA

          -  In good health and capable of undergoing THA with spinal block and sedation anesthesia

          -  No additional planned surgeries during the course of the trial

          -  Willing and able to complete the study procedures and pain scales and to communicate
             meaningfully in English

        Key Exclusion Criteria:

          -  A body mass index greater than 40

          -  Known bleeding disorder or is taking agents affecting coagulation preoperatively

          -  A medical condition that could adversely impact the patient's participation, safety,
             or conduct of the study

          -  Diabetes mellitus with a known HbA1C&gt;9.5 or a history of prolonged uncontrolled
             diabetes

          -  Previous hip arthroplasty of the same hip

          -  Participated in another clinical trial within 30 days of the planned hip surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaun Comfort, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Anesiva, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Houghton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Anesiva, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research, Inc.</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Webster Orthopaedic Medical Group</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco - Mt. Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Medical Research, Inc.</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sewickley Valley Hospial</name>
      <address>
        <city>Sewickley</city>
        <state>Pennsylvania</state>
        <zip>15143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Medical Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.anesiva.com/wt/page/pipeline</url>
    <description>Anesiva Home page</description>
  </link>
  <link>
    <url>http://www.anesiva.com/wt/page/adlea</url>
    <description>ADLEA Product Information</description>
  </link>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>May 1, 2009</last_update_submitted>
  <last_update_submitted_qc>May 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Shaun Comfort, MD</name_title>
    <organization>Anesiva, Inc.</organization>
  </responsible_party>
  <keyword>THA, Total hip arthroplasty, total hip replacement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

